{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:59:54Z","timestamp":1761487194864},"reference-count":11,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T00:00:00Z","timestamp":1091145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:p><jats:bold>Abstract\u2003<\/jats:bold><jats:bold> Background:\u2002<\/jats:bold> Intravesical oxybutynin chloride with hydroxypropylcellulose (HPC) (modified intravesical oxybutynin) has been reported to be effective for treatment of overactive bladder. We reported the short\u2010term effects of modified intravesical oxybutynin previously. In the present article, we detail the results of a 3\u2010year follow\u2010up study of patients from our previous analysis and report the efficacy and side\u2010effects of modified intravesical oxybutynin.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Modified intravesical oxybutynin (5\u2003mg\/10\u2003mL, twice a day) was applied for more than 3\u2003years to six neurogenic overactive detrusor patients (three men and three women, average age 53.3\u2003years) who were not satisfied with oral anticholinergic agents or the other therapy. A cystometogram (CMG) was performed before, 1\u2003week after and 3\u2003years after the start of modified intravesical oxybutynin treatment. We evaluated the patient's satisfaction of this treatment after 4\u2003weeks and again after 3\u2003years. We compared the patients\u2019 answers before and after the therapy (excellent, good, fair, unchanged and worse). We also monitored systemic and topical side\u2010effects in these patients during this period.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> CMG studies showed that two of six patients no longer exhibited uninhibited contraction 1\u2003week after the treatment and that the cystocapacity of patients before, 1\u2003week after and 3\u2003years after the initial modified intravesical oxybutynin was 129.7\u2003\u00b1\u200319.4, 283.5\u2003\u00b1\u200340.4 and 286.8\u2003\u00b1\u200338.1\u2003mL, respectively. For the evaluation of patients\u2019 satisfaction with this treatment, four patients considered the therapy excellent and one patient described it as good after both 4\u2003weeks and after 3\u2003years. Two patients dropped out of the study; one developed left ureteral cancer (2.25\u2003years) and the other developed ileus (1.5\u2003years). Dry mouth and acute cystitis were observed in both patients.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Modified intravesical oxybutynin is an effective and relatively safe option of therapy for overactive bladder patients. However, this therapy requires careful observation for emergent side\u2010effects.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2004.00871.x","type":"journal-article","created":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T14:47:56Z","timestamp":1091198876000},"page":"592-596","source":"Crossref","is-referenced-by-count":20,"title":["Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3\u2003years experience"],"prefix":"10.1111","volume":"11","author":[{"given":"MOTOAKI","family":"SAITO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKESHI","family":"WATANABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FUMIE","family":"TABUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENJI","family":"OTSUBO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEISUKE","family":"SATOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IKUO","family":"MIYAGAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,7,30]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36663-6"},{"key":"e_1_2_5_3_2","first-page":"306","article-title":"New intravesical oxybutynin hydrochloride used for the treatment of neurogenic bladder dysfunction","volume":"15","author":"Mizunaga M","year":"1996","journal-title":"Neurourol. Urodyn."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62828-3"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000475078"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37845-X"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6777(2000)19:6<683::AID-NAU6>3.0.CO;2-R"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0022-5347(17)41304-8","article-title":"Topical oxybutynin chloride for relaxation of dysfunctional bladders","volume":"141","author":"Brendler CB","year":"1988","journal-title":"J. Urol."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(93)90098-U"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0022-5347(17)35130-3","article-title":"The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia","volume":"151","author":"Kasabin NG","year":"1994","journal-title":"J. Urol."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65238-8"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000019701"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2004.00871.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2004.00871.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:52:45Z","timestamp":1696945965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2004.00871.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,30]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1442-2042.2004.00871.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2004.00871.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,30]]}}}